Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 12, 2025

XRP 2030 Price Prediction: Can XRP Reach $25 or Will $5 Be the Peak?

View original at finance.yahoo.com
XRP 2030 Price Prediction: Can XRP Reach $25 or Will $5 Be the Peak? Sundays Photography / Shutterstock.com Quick Read XRP traded between $1.75 and $3.65 over six months and now sits around $2.05…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In base case, XRP could trade between $8 and $12 by 2030 with steady but not dramatic adoption

    80% confidence
  • XRP can reach $25 by 2030 if CBDC pilots mature, privacy features gain traction among enterprises, and stablecoins like RLUSD reach multi-billion-dollar scale

    80% confidence
  • In bearish case, XRP could trade between $3 and $5 by 2030 if institutional rollout loses momentum

    80% confidence
  • A $25 XRP by 2030 requires $1.4T market cap and trillions in annual settlement volume through XRPL

    80% confidence
  • Many banks use ODL for settlement, but still avoid holding XRP on their books due to price swings creating audit and compliance headaches

    80% confidence
  • XRP traded between $1.75 and $3.65 over six months and now sits around $2.05

    80% confidence
  • In bullish case, XRP could reach $20-$25 range by 2030 with broad corridor coverage, active CBDC connections, and maturing privacy-powered settlement flows

    80% confidence
  • Ripple partners with six central banks on CBDC pilots including Georgia and Hong Kong

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com